Lv3
318 积分 2023-12-26 加入
POS0017 Bispecific T Cell-Engaging Antibodies to Target TRBV9+ Autoreactive T Cells in Axial Spondyloarthritis
25天前
已完结
T cell engagers in autoimmune diseases
25天前
已完结
A bispecific CD3×CD19 antibody for systemic lupus erythematosus: a phase 1 trial
1个月前
已完结
Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia
1个月前
已完结
Production and characterization of a panel of anti-mouse placenta-specific protein 1 (plac1) monoclonal antibodies
1个月前
已完结
The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer
1个月前
已完结
Antibody-drug Conjugate Targeting of the Surface-Displayed Cancer Testis Antigen-LY6K on Epithelial-Lineage Solid Tumors
1个月前
已完结
Treatment-related adverse events of CD3-based T cell-engaging bispecific antibodies in patients with cancer: a meta-analysis of clinical trials
1个月前
已完结
A Mucin 16 bispecific T cell–engaging antibody for the treatment of ovarian cancer
1个月前
已完结
Population Pharmacokinetics of Tarlatamab, a Half-Life Extended DLL3-Directed Bispecific T-Cell Engager in Patients with Previously Treated Small Cell Lung Cancer
2个月前
已完结
皖公网安备34019202002308
